FDA issued a Warning Letter to Guangzhou Baiyunshan Pharmaceutical Co., Ltd. on 11/1/2017 as a result of this inspection.
483 Guangzhou Baiyunshan Pharmaceutical May 2017

483 Guangzhou Baiyunshan Pharmaceutical May 2017

Joel Hustedt FDA$119.00 - Available Now

FDA investigators audited the Guangzhou Baiyunshan Pharmaceutical - Guangzhou, China facility and issued inspectional observations (via FDA 483) on 25 May 2017.

Product details

  • Category: Human Drugs
  • Inspection end: 25 May 2017
  • Location: Guangzhou, China
  • FEI: 3004506176
Add To Cart